Name: India, Pakistan and Cambodia Tuberculosis Treatment Market Size, Share, Industry, Forecast and outlook (2024-2031)
Brand: DataM Intelligence
SKU: CPG2863
Price: 3175 USD
Availability: InStock

India, Pakistan & Cambodia Tuberculosis Treatment Market 2024-2031

India, Pakistan and Cambodia Tuberculosis Treatment Market Size, Share, Industry, Forecast and outlook (2024-2031)

<h2>India, Pakistan &amp; Cambodia Tuberculosis Treatment Market is segmented&nbsp;By Therapy Type (First Line Therapy (Isoniazid (INH), Rifampicin (RIF), Ethambutol (EMB), Pyrazinamide (PZA), Streptomycin (SM), Others), Second Line Therapy (Capreomycin (Capastat), Streptomycin, Levofloxacin (Levaquin), Ethionamide (Trecator), Others), Combination Drugs),&nbsp;By Disease Type (Active TB, Latent TB),&nbsp;By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others),&nbsp;and By Region &ndash; Share, Size, Outlook, and Opportunity Analysis, 2024-2031</h2>

&nbsp;

<h3>Market Overview</h3>

<blockquote>
The India, Pakistan &amp; Cambodia Tuberculosis Treatment Market is expected to grow at a high&nbsp;<a href="https://www.datamintelligence.com/download-sample/india-pakistan-and-cambodia-tuberculosis-treatment-market">CAGR</a>&nbsp;during the forecasting period (2024-2031).
</blockquote>

Tuberculosis (TB), known as poor man&rsquo;s disease, is caused by Mycobacterium tuberculosis germs that are spread from person to person through the air.

TB usually affects the lungs and affects the other parts of the body such as the brain, the kidneys, or the spine.

In 2017, the number of deaths by tuberculosis in Cambodia amounted to 19 deaths per hundred thousand people.

By drug type, the tuberculosis drug market is segmented into first-line drugs therapy, second-line drugs therapy, and combination drugs therapy.

The first-line drug therapy segment holds the most significant share in 2018, owing to the usage of a combination of first-line drugs, around 90% of individuals with drug-susceptible TB can be cured. Any delay and discontinuity during this treatment can lead to treatment failure and the emergence of drug resistance.

The first-line anti-TB regimen comprises a daily dosage of isoniazid, rifampicin, pyrazinamide, and ethambutol for two months, followed by a daily dosage of isoniazid and rifampicin for four months

&nbsp;

<h2 style="background:#eeeeee; border:1px solid #cccccc; padding:5px 10px">Table of Contents</h2>

<ol>
	<li>
	Methodology and Scope

	<ol>
		<li>
		Research Methodology
		</li>
		<li>
		Research Objective and Scope of the Report
		</li>
	</ol>
	</li>
	<li>
	Market Definition and Overview
	</li>
	<li>
	Executive Summary

	<ol>
		<li>
		Market Snippet by Therapy Type
		</li>
		<li>
		Market Snippet by Disease Type
		</li>
		<li>
		Market Snippet by Distribution Channel
		</li>
		<li>
		Market Snippet by Country
		</li>
	</ol>
	</li>
	<li>
	Market Dynamics

	<ol>
		<li>
		Market Impacting Factors
		</li>
		<li>
		Drivers

		<ol>
			<li>
			XX
			</li>
			<li>
			XX
			</li>
		</ol>
		</li>
		<li>
		Restraints:

		<ol>
			<li>
			XX
			</li>
			<li>
			XX
			</li>
		</ol>
		</li>
		<li>
		Opportunity
		</li>
		<li>
		Impact Analysis
		</li>
	</ol>
	</li>
	<li>
	Industry Analysis

	<ol>
		<li>
		Porter&#39;s Five Forces Analysis
		</li>
		<li>
		Epidemiology
		</li>
		<li>
		Pipeline Analysis
		</li>
		<li>
		Regulatory Analysis
		</li>
		<li>
		Supply Chain Analysis
		</li>
		<li>
		Pricing Analysis
		</li>
		<li>
		Unmet Needs
		</li>
	</ol>
	</li>
	<li>
	COVID-19 Analysis

	<ol>
		<li>
		Analysis of Covid-19 on the Market
		</li>
		<li>
		Pricing Dynamics Amid Covid-19
		</li>
		<li>
		Demand-Supply Spectrum
		</li>
		<li>
		Government Initiatives Related to the Market During Pandemic
		</li>
		<li>
		Manufacturers Strategic Initiatives
		</li>
		<li>
		Conclusion
		</li>
	</ol>
	</li>
	<li>
	By Therapy Type

	<ol>
		<li>
		Introduction

		<ol>
			<li>
			Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy Type&nbsp;&nbsp;
			</li>
			<li>
			Market Attractiveness Index, By Therapy Type&nbsp;
			</li>
		</ol>
		</li>
		<li>
		First Line Therapy*

		<ol>
			<li>
			Introduction
			</li>
			<li>
			Market Size Analysis, US$ Million, 2019-2027 and Y-o-Y Growth Analysis (%), 2020-2027
			</li>
			<li>
			Isoniazid (INH)
			</li>
			<li>
			Rifampicin (RIF)
			</li>
			<li>
			Ethambutol (EMB)
			</li>
			<li>
			Pyrazinamide (PZA)
			</li>
			<li>
			Streptomycin (SM)
			</li>
			<li>
			Others
			</li>
		</ol>
		</li>
		<li>
		Second Line Therapy

		<ol>
			<li>
			Capreomycin (Capastat)
			</li>
			<li>
			Streptomycin
			</li>
			<li>
			Levofloxacin (Levaquin)
			</li>
			<li>
			Ethionamide (Trecator)
			</li>
			<li>
			Others
			</li>
		</ol>
		</li>
		<li>
		Combination Drugs
		</li>
	</ol>
	</li>
	<li>
	By Disease Type

	<ol>
		<li>
		Introduction

		<ol>
			<li>
			Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
			</li>
			<li>
			Market Attractiveness Index, By Disease Type
			</li>
		</ol>
		</li>
		<li>
		Active TB *

		<ol>
			<li>
			Introduction
			</li>
			<li>
			Market Size Analysis, US$ Million, 2019-2027 and Y-o-Y Growth Analysis (%), 2020-2027
			</li>
		</ol>
		</li>
		<li>
		Latent TB
		</li>
	</ol>
	</li>
	<li>
	By Distribution Channel

	<ol>
		<li>
		Introduction

		<ol>
			<li>
			Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel Segment
			</li>
			<li>
			Market Attractiveness Index, By Distribution Channel Segment
			</li>
		</ol>
		</li>
		<li>
		Hospital Pharmacies* *

		<ol>
			<li>
			Introduction
			</li>
			<li>
			Market Size Analysis, US$ Million, 2019-2027 and Y-o-Y Growth Analysis (%), 2020-2027
			</li>
		</ol>
		</li>
		<li>
		Retail Pharmacies
		</li>
		<li>
		Online Pharmacies
		</li>
		<li>
		Others
		</li>
	</ol>
	</li>
	<li>
	By Country

	<ol>
		<li>
		Introduction

		<ol>
			<li>
			Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
			</li>
			<li>
			Market Attractiveness Index, By Country
			</li>
		</ol>
		</li>
		<li>
		India

		<ol>
			<li>
			Introduction
			</li>
			<li>
			Key Region-Specific Dynamics
			</li>
			<li>
			Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy Type
			</li>
			<li>
			Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
			</li>
			<li>
			Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
			</li>
		</ol>
		</li>
		<li>
		Pakistan

		<ol>
			<li>
			Introduction
			</li>
			<li>
			Key Region-Specific Dynamics
			</li>
			<li>
			Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy Type
			</li>
			<li>
			Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
			</li>
			<li>
			Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
			</li>
		</ol>
		</li>
		<li>
		Cambodia

		<ol>
			<li>
			Introduction
			</li>
			<li>
			Key Region-Specific Dynamics
			</li>
			<li>
			Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy Type
			</li>
			<li>
			Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
			</li>
			<li>
			Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
			</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>
	Competitive Landscape

	<ol>
		<li>
		Competitive Scenario
		</li>
		<li>
		Market Positioning/Share Analysis
		</li>
		<li>
		Mergers and Acquisitions Analysis
		</li>
	</ol>
	</li>
	<li>
	Company Profiles

	<ol>
		<li>
		Pfizer.*

		<ol>
			<li>
			Company Overview
			</li>
			<li>
			Product Portfolio and Description
			</li>
			<li>
			Key Highlights
			</li>
			<li>
			Financial Overview
			</li>
		</ol>
		</li>
		<li>
		Novartis
		</li>
		<li>
		Lupin Ltd.
		</li>
		<li>
		Johnson &amp; Johnson Services, LLC
		</li>
		<li>
		Macleods Pharmaceuticals Ltd
		</li>
		<li>
		Otsuka Pharmaceutical Co., Ltd.
		</li>
		<li>
		Others&nbsp; (List Not Exhaustive)
		</li>
	</ol>
	</li>
	<li>
	DataM Intelligence

	<ol>
		<li>
		Appendix
		</li>
		<li>
		About Us and Services
		</li>
		<li>
		Contact Us
		</li>
	</ol>
	</li>
</ol>

India, Pakistan and Cambodia Tuberculosis Treatment Market Size, Share, Industry, Forecast and outlook (2024-2031)

Tuberculosis Drug Market Size, Share, Industry, Forecast and outlook (2024-2031)

Published: 2024 January 09

Starting from

Tuberculosis Testing Market Outlook, Demand, Opportunities, Competitive Analysis and Market Forecast 2023-2030

Published: 2023 September 08

Starting from